Ciudadela

Researchers are evaluating the safety, tolerability, and clinical activity of an unconjugated belantamab antibody alone and in combination with other treatments for people with refractory multiple myeloma RRMM. This study includes participants who have had several prior therapies, including a proteasome inhibitor, lenalidomide, and an anti-CD38 monoclonal antibody. The trial has three parts focusing on different combinations and dosages to better understand how these treatments work in this condition. Participants will receive one of several treatments depending on the study part in Part 1, they receive escalating doses of the unconjugated belantamab antibody alone in Part 2, the antibody is combined with a fixed dose of belantamab mafodotin, given as separate drugs and in Part 3, the antibody is combined with a pomalidomide-dexamethasone standard care backbone. Treatment in Parts 1 and 2 continues until disease progression, after which participants may opt to receive belantamab mafodotin alone. During the study, participants are monitored for adverse events and dose-limiting toxicities, as well as changes in laboratory and vital signs parameters. Researchers also track ocular events using a specific visual acuity scale. The study measures treatment responses, including overall response rates and very good partial response rates, along with drug levels in the blood. Participants are followed for up to 52 months to assess treatment effects and safety under medical supervision throughout the trial.

Researchers are evaluating whether the combination of vicadrostat BI 690517 and empagliflozin helps adults with heart failure who have symptoms and a left ventricular ejection fraction LVEF of 40% or more. This phase III study is designed to compare the effects of vicadrostatempagliflozin tablets versus placeboempagliflozin tablets on heart failure outcomes. The study aims to understand if this combined treatment improves health and reduces heart-related events. Participants are randomly assigned to one of two groups one group takes vicadrostat plus empagliflozin tablets once a day, and the other takes placebo plus empagliflozin tablets once a day. The study has no fixed duration and continues as long as participants benefit and tolerate the treatment. Throughout the study, participants visit their doctors regularly for health checks, and study staff may also contact them by phone to monitor well-being and any side effects. During the study, researchers monitor participants health through regular doctor visits and phone contacts. They collect data on heart-related events such as cardiovascular death, hospitalizations for heart failure, and urgent visits for heart failure over up to 42 months. Participants also answer questions about their symptoms and well-being. The study carefully tracks safety and treatment tolerance while gathering information to determine if the combined treatment helps people with heart failure.

Researchers are examining the effect of abelacimab compared to a placebo in patients with atrial fibrillation AF who are considered unsuitable for oral anticoagulation therapy. This Phase 3 study focuses on high-risk patients with AF to evaluate whether abelacimab can reduce the occurrence of ischemic stroke or systemic embolism. The study is led by Anthos Therapeutics, Inc. and aims to address treatment options in patients where traditional anticoagulation is deemed inappropriate. Participants are randomly assigned in equal numbers to receive either abelacimab 150 mg or a matching placebo by subcutaneous injection once a month. The study consists of three periods a screening period lasting up to 60 days, a double-blind treatment period that continues until at least 111 patients experience a primary endpoint event, and an end-of-treatment visit. Following this, participants may enter a 30-day follow-up or an optional open-label extension to receive abelacimab, depending on eligibility and regulatory approval. During the study, participants undergo assessments to monitor stroke, systemic embolism, and bleeding events, with the primary outcomes measured up to 30 months. Safety is tracked by recording bleeding events classified by the Bleeding Academic Research Consortium. Secondary outcomes include cardiovascular and all-cause mortality and other thrombotic events. The study also involves regular monitoring and follow-up visits to assess efficacy and safety throughout the treatment and observation periods.